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Abstract
Background: We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is
expressed on activated TH2 but not TH1 cells. Here we measured cytokine expression in human
ex vivo TH2 cells upon activation with anti-CD3/28 and challenge with an NKG2A-specific agonist.
Methods: TH2 cells were purified from healthy volunteers and activated with anti-CD3/28 in the
presence and absence of NKG2A-specific agonist. IL-4 was used as a marker of TH2 effector
function and measured by flow cytometry.
Results: Activation of TH2 cells increased NKG2A positivity from (Mean ± SE) 7.3 ± 2.4% to 13.7
± 3.8%; (p = 0.03). The presence of NKG2A agonist did not significantly alter NKG2A expression,
however, the percentage of activated TH2 cells expressing intracellular IL-4 decreased from 25.5
± 6.8% to 9.3 ± 4.8% (p = 0.001).
Conclusion: We show that signalling through NKG2A suppresses TH2 effector function. This may
provide a means to modulate Th1/Th2 balance in diseases where Th2 cytokines predominate.
Background
NKG2A [Swiss-Prot: P26715] is an inhibitory C-type lec-
tin most commonly found on natural killer (NK) cells and
cytotoxic T lymphocytes[1-4]. The receptor-ligand bind-
ing of NKG2A to MHC class Ib antigen HLA -E[5-10]
induces an immunoreceptor tyrosine-based inhibition
motif (ITIM) that suppresses effector cell cytotoxic activ-
ity[11-14]. It has been reported that this inhibition of
cytotoxicity is important in NKG2A's role in the modula-
tion of cytotoxic immune response to viruses[15-20] and
cancers[21,22].
Our previous report on NKG2A showed that it is
expressed on activated human TH2 but not TH1 cells[23].
Based on our data, we proposed a model where disease
states characterized by decreases in HLA-E expression, for
example as seen in melanoma[24] and herpes simplex
virus infection[25], would lead to decreased agonism at
TH2 NKG2A receptors. The resultant decrease in NKG2A
inhibitory signaling would lead to relatively increased
TH2 cell effector function, exacerbating Th1/Th2 imbal-
ance in diseases where that balance is relevant.
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model, we hypothesized that ligation of NKG2A receptors
on activated TH2 cells would be expected to lead to down-
stream suppression of interleukin (IL)-4 expression[23].
Here, we test this hypothesis using purified human ex vivo
TH2 cells with activation by anti-CD3/CD28 antibodies
and challenge with an NKG2A-specific agonist.
Methods
Participants
Apparently healthy, non-atopic, non-asthmatic volun-
teers between the ages of 18 and 50 years had 60 mL of
venous blood drawn directly into ethylenediamine-
tetraacetic acid (EDTA) following written informed con-
sent. The investigation was approved by the hospital's
Institutional Review Board and General Clinical Research
Center (GCRC) Advisory Committee and performed in
the hospital GCRC.
TH2 cell isolation
Cell separation procedures were begun within 30 minutes
of blood collection. TH2 cells were isolated from whole
blood as we previously described[23]. Briefly, EDTA-
whole blood was centrifuged at low speed to allow
removal of platelet-rich plasma. The remaining cells were
diluted and centrifuged over Ficoll Paque PLUS™ (Amer-
sham Biosciences, Piscataway, NJ) density medium to iso-
late the peripheral blood mononuclear cell (PBMC) layer.
The PBMCs were counted by hemocytometer to assure a
concentration less than 8 × 107 cells/mL. TH2 lym-
phocytes were negatively isolated from the PBMCs using
StemSep™ magnetic gravity columns (StemCell Technolo-
gies, Vancouver, BC) with a monoclonal antibody cocktail
we previously validated for TH2 enrichment to 84%
purity[23]. Eluted TH2 cells were immediately placed in
cell culture.
Cell culture
Four cell culture conditions were used (Table 1), includ-
ing combinations of resting and activated TH2 cells and
challenge with an NKG2A agonist. All TH2 cells, except
negative controls, were pre-treated with IgG2a (R&D Sys-
tems, Minneapolis, MN) to prevent non-specific antibody
binding. Plates for activated TH2 cell culture conditions
were prepared with 10 μg/mL each of plate-bound anti-
CD3 (Clone SK7: BD Biosciences, San Diego, CA) and sus-
pended anti-CD28 antibodies (Clone 15E8: Chemicon
International/Upstate USA, San Francisco, CA). The
enriched TH2 cells (< 1 × 106 cells/mL) were aliquoted
equally into each of the four cell culture conditions sus-
pended in HB 101 Basal Media (Irvine Scientific, Santa
Ana, CA), 10% HB Basal Supplement (Irvine Scientific),
10% autologous plasma, 10% Penicillin/Streptomycin
(Sigma-Aldrich, St. Louis, MO), and 1% Gentamicin
(Sigma-Aldrich). Negative control wells contained TH2
cells in culture medium alone.
The NKG2A agonist used for these experiments was an
anti-NKG2A antibody (Clone 131411, R&D Systems) that
specifically binds the NKG2A receptor and elicits its inhib-
itory signal[26,27]. Cells were treated with either 10 μg/
mL of soluble or plate-bound anti-NKG2A antibody as
per these previous reports at culture inception and every
24 hours. Results for soluble and plate-bound anti-
NKG2A antibody were similar so only results from solu-
ble treatments were used for analysis (Data not shown).
Likewise, isotype control wells were treated every 24 hours
with 10 μg/mL of anti-IgG2a (R&D Systems), the isotype
for the anti-NKG2A antibody. All cell culture conditions
were maintained for 48 hours at 37°C and 5% CO2.
Flow cytometry
Post-culture TH2 cells underwent a series of incubations
with fluorescent-labeled monoclonal antibodies, as well
as permeablization and fixation with 2% paraformalde-
hyde. Four-color flow cytometry (FACSCalibur™ System,
BD) was performed with varying combinations of anti-
CD3-PerCP (BD), anti-CD4-FITC (BD), anti-CD4-APC
(BD), anti-CD8-FITC (BD), anti-NKG2A-APC (R&D Sys-
tems), anti-NKG2C-PE (R&D Systems), anti-IFN-γ-FITC
(BD), and anti-IL-4-PE (BD) using appropriate isotype
and negative (unlabeled cells) controls. Cells were gated
for viable TH lymphocytes using forward- and side-scatter
properties and CD3+CD4+ double positivity. Flow data
were analyzed with FlowJo 7.1 (Tree Star, Inc., Ashland,
OR).
Data analysis
Within- and between-culture condition comparisons were
made for percent positive cells and geometric mean fluo-
Table 1: Description of Cell Culture Conditions
Condition Cell Stimulants (10 μg/mL each) Added Antibody* (10 μg/mL each)
Positive Control anti-CD3 and anti-CD28 None
Anti-NKG2A Antibody anti-CD3 and anti-CD28 anti-NKG2A
Isotype Control anti-CD3 and anti-CD28 IgG2a
Negative Control None None
*Added every 24 hours.Page 2 of 6
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with SPSS 13 (SPSS, Chicago, IL) using paired T-tests.
Results
A total of ten apparently healthy, non-atopic, non-asth-
matic adult volunteers were enrolled in this study. Both
genders and a diverse group of ethnicities and races were
represented among the participants.
Following culture in the four distinct conditions (positive
control, anti-NKG2A antibody, isotype control, and nega-
tive control) TH2 cell samples were examined by four-
color flow cytometry to confirm the expected rise in cells
positive for NKG2A surface expression. The cultured cells
were > 97% pure CD3+CD4+CD8- TH cells. We found sig-
nificant up-regulation of TH2 NKG2A positivity from 7.3
± 2.3% in negative controls to 13.7 ± 3.8% in positive
controls (p = 0.03) consistent with our previously pub-
lished data[23]. There was no significant difference in the
surface expression of NKG2A (16.0 ± 4.0%) on the acti-
vated TH2 cells cultured in the presence of anti-NKG2A
antibodies and the positive controls. Results for soluble
and plate-bound anti-NKG2A antibody were similar so
only results from soluble treatments were used for analy-
sis. Additionally, there was no appreciable change in the
low level expression of activating NKG2C (data not
shown). This was also consistent with our previous find-
ings[23].
In order to assess the impact of NKG2A signaling on TH2
cell effector function following activation through the
TCR, we performed flow cytometry for intracellular
expression of IL-4 and IFN-γ. There was significant up-reg-
ulation of intracellular IL-4 from 6.7 ± 4.6% in negative
controls to 25.5 ± 6.8% in positive controls (p = 0.003).
(Table 2 and Figure 1) When TH2 cells were activated in
culture in the presence of anti-NKG2A antibodies, the
intracellular expression of IL-4 fell from 25.5 ± 6.8% to
9.3 ± 4.8% (p = 0.001) overall. (Table 2 and Figure 1) This
level of IL-4 expression was not significantly different
from the negative controls. As before, results for soluble
and plate-bound anti-NKG2A antibody were similar so
only results from soluble treatments were used for analy-
sis. Additionally, double-staining of activated TH2 cells
for surface NKG2A and intracellular IL-4 showed the
reduction in IL-4 expression occurs mainly among the
NKG2A positive cells. (Figure 2)
We also examined expression of IFN-γ and found similar
changes in intracellular expression. Negative control
expression was 4.8 ± 0.8%. This increased to 7.7 ± 1.3% in
positive controls (p = 0.05) and fell to 5.5 ± 1.3% in the
presence of anti-NKG2A antibody (p = 0.04). This level of
expression was not different from negative controls.
Discussion
Using a monoclonal antibody cocktail we developed for
the negative isolation of human TH2 cells, we confirmed
our previous work showing a significant increase in
Table 2: Between Cell Culture Condition Comparisons of TH2 Cell Positivity for IL-4 and IFN-γ
Condition IL-4 Positive (%) Fold IL-4 MFI IFNγ Positive (%) Fold IFNγ MFI
Positive Control (CD3/
CD28)
Mean 25.5% 22.47 7.7% 7.43
SEM 6.8% 12.26 1.3% 1.42
p-value (Negative Control) 0.003 0.03 0.05 0.05
p-value (Isotype Control) 0.11 0.18 0.35 0.24
Anti-NKG2A Antibody 
(CD3/CD28 + anti-NKG2A)
Mean 9.3% 4.39 5.5% 5.29
SEM 4.8% 1.81 1.3% 1.50
p-value (Positive Control) 0.001 0.01 0.04 0.01
p-value (Isotype Control) 0.005 0.066 0.427 0.234
Isotype Control (CD3/CD28 
+ IgG2a)
Mean 23.7% 7.81 4.9% 6.50
SEM 1.0% 0.72 2.7% 0.43
p-value - - - -
Negative Control (Culture 
Medium Alone)
Mean 6.7% 2.76 4.8% 4.83
SEM 4.6% 0.63 0.8% 1.60
p-value - - - -
p ≤ 0.05 in bold.Page 3 of 6
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tion of TH2 cells[23]. Here, we tested the hypothesis that
activated TH2 cell effector function is diminished in the
presence of NKG2A signaling.
We induced NKG2A signaling using a monoclonal anti-
body specific for the NKG2A receptor that has been
shown to be an agonist and cause suppression of NK cell
cytotoxicity in P815 target cells[27]. We used a magnetic
gravity column isolation to obtain quiescent human
peripheral blood TH2 cells. These TH2 cells were bound
with the NKG2A agonist antibody and then studied for
downstream signaling of CD3/CD28. Activated NKG2A+
TH2 cells cultured with this NKG2A agonist showed a sig-
nificant decrease in effector function indicated by intrac-
ellular IL-4 expression measured by flow cytometry. As
NKG2A is expressed on TH2 but not TH1 cells [23], our
ligation of NKG2A would have the functional conse-
quence of altering Th1/Th2 cytokine ratios. To our knowl-
edge, this is the first ex vivo immune modulation of
human TH2 cells.
The data presented here suggest that use of this NKG2A
agonist antibody could modulate Th1/Th2 balance
toward Th1 and thus modulate inflammatory responses.
Consistent with this model, Kawamura, et al. used anti-
NKG2A monoclonal antibodies to restrict donor T cell
expansion and suppress inflammation in a murine model
of acute graft-versus-host disease[28]. Our data suggest
that this may also be possible in human diseases like
asthma, colitis, and autoimmune diseases where Th1/Th2
cytokine balance is important.
Our finding that the NKG2A receptor is capable of modu-
lating TH2 cell effector function is analogous to its pur-
pose on CD8+ cytotoxic T cells, where it helps prevent
cytotoxicity of HLA-E expressing cells. In TH2 cells it
appears that there is concomitant binding of NKG2A to
HLA-E along with the CD4+-TCR to MHC class II. This
parallel receptor-ligand binding likely results in transmis-
sion of an inhibitory signal from NKG2A via SHP-1 and
SHP-2 along with the activating signal from the TCR.
Given the lack of NKG2A on activated TH1 cells, this
could lead to a relatively robust TH2 response.
As in our previous study, we continued to find sizeable
inter-individual variability in the level of NGK2A expres-
sion before and after TH2 cell activation. This has been
described previously for NKG2 receptors in rhesus mon-
keys [29] and is either indicative of dynamic switching of
NKG2 receptor expression between subtypes or individual
genetic differences.
Conclusion
In conclusion, we identified significant suppression of IL-
4 expression in activated TH2 cells via NKG2A binding
and ultimate TCR signaling inhibition. Extrapolated to
clinical scenarios where HLA-E and thus NKG2A binding
Comparison of intracellular IL-4 expression between culture conditionsFigure 1
Comparison of intracellular IL-4 expression between culture conditions. Comparison of TH2 lymphocytes cultured 
in each of four culture conditions. Mean ± SEM percent cells positive for intracellular IL-4 is shown in this graph.Page 4 of 6
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could be expected to exhibit a relatively robust response
and that this response could potentially be modulated by
NKG2A agonist. This represents a new aspect of Th1/Th2
balance in inflammation with possible clinical implica-
tions.
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